Contractile myofibroblasts are responsible for the irreversible alterations of the lung parenchyma that hallmark pulmonary fibrosis. In response to lung injury, a variety of different precursor cells can become activated to develop myofibroblast features, most notably formation of stress fibers and expression of a-smooth muscle actin. Starting as an acute and beneficial repair process, myofibroblast secretion of collagen and contraction frequently becomes excessive and persists. The result is accumulation of stiff scar tissue that obstructs and ultimately destroys lung function. In addition to being a consequence of myofibroblast activities, the stiffened tissue is also a major promoter of the myofibroblast. The mechanical properties of scarred lung and fibrotic foci promote myofibroblast contraction and differentiation. One essential element in this detrimental feedforward loop is the mechanical activation of the profibrotic growth factor transforming growth factor-b1 from stores in the extracellular matrix. Interfering with myofibroblast contraction and integrinmediated force transmission to latent transforming growth factor-b1 and matrix proteins are here presented as possible therapeutic strategies to halt fibrosis.
Keywords: TGF-b1 activation; stress fiber; contraction; matrix stiffness; integrin Pulmonary fibrosis is a dysregulated reparative response of the lung that is characterized by uncontrolled myofibroblast proliferation and profibrotic activity, resulting in the excessive deposition, contraction, and stiffening of collagenous extracellular matrix (ECM) (1) (2) (3) (4) . Instrumental for the development of high contractile forces and the main defining feature of myofibroblasts is the neoexpression of a-smooth muscle actin (a-SMA) (Figure 1) , which leads to a qualitative change in the organization and function of stress fibers (5, 6) . Although a small population of a-SMA-negative but microfilament bundle-forming contractile fibroblasts resides in normal alveolar septa (7) , myofibroblast differentiation and overactivity has been directly correlated with progression of lung fibrosis and deposition of collagen type I (8) (9) (10) . Accumulation of this fibrotic scar tissue within the otherwise delicate interstitium results in both decreased lung compliance (i.e., increasing stiffness) and loss of gas exchange, ultimately rendering patients unable to breathe (2) . A number of review articles recently elaborated on various aspects of myofibroblast biology and its contribution to pulmonary fibrosis (2, 11, 12) . Here, I will summarize new findings and concepts on how myofibroblast activities change the mechanical properties of lung tissue, and how in turn the mechanical environment in the fibrotic lung can control myofibroblast differentiation and action. It appears that this self-perpetuating mechanical loop is one major contributor to the progression of fibrosis.
ORIGINS OF THE MYOFIBROBLAST
By sharing contractile features with smooth muscle and collagen secreting activity with fibroblasts, myofibroblasts appear to be situated in a continuous differentiation spectrum ranging from fibroblastic to smooth muscle cells (SMCs). The controlled and transient appearance of myofibroblasts is important for restoring the integrity of damaged tissues by forming a collagenous scar (6) . The scar protects injured organs from further damage upon mechanical challenge, such as the heart after myocardial infarction (13) (14) (15) , skin after trauma (16) , and tendon, bone, and cartilage after fracture or rupture (17) (18) (19) . However, in many conditions, myofibroblasts go out of control and resist their physiological clearance through apoptosis (11, (20) (21) (22) (23) (24) . In fibrosis, the excessive and detrimental myofibroblast activities turn beneficial tissue repair into devastating tissue deformation (25) . Fibrosis can affect virtually all organs, including the lung (12, 26, 27) , skin after burns (28) and in systemic sclerosis (29, 30) , palmar fascia in Dupuytren's disease (31) , heart (14) , liver (32) (33) (34) , and kidney (35, 36) . Myofibroblasts activated during the stroma reaction to epithelial tumors generate the chemical and mechanical environment that promotes tumor progression (37, 38) .
Healthy normal tissues usually do not contain myofibroblasts, which are formed de novo in response to an insult. Consistent with our body's need to rapidly repair injured organs and the great diversity of organs that are prone to fibrosis, myofibroblasts can be recruited from a multitude of different progenitor cells (38) (39) (40) . Many myofibroblast precursors are mesenchymal and locally available, including fibroblasts and mesenchymal progenitor cells that reside in the connective tissue architecture of all organs. Myofibroblasts are also activated from SMCs in the arterial wall, pericytes in vascularized tissues, chondrocytes in cartilage, and osteoblasts in bone (39) . In the diseased liver, hepatic stellate cells from meso/endodermal origin contribute to the myofibroblast population together with portal fibroblasts (41) . In the lung, a number of different myofibroblast precursors have been identified in addition to local fibroblasts (42) . Like in the kidney (43, 44) and tumors (45), epithelial and/or endothelial cells have been shown to generate lung myofibroblasts by mesenchymal transition (EMT) (46-49) ( Figure 2 ). It has recently been suggested that acquisition of the myoid phenotype is associated with EMT but controlled by distinct signaling pathways (50, 51) . Other studies seem to exclude a contribution of EMT to myofibroblast formation in human and mouse lungs (52, 53) . Since EMT has also been questioned in kidney fibrosis (54) , the debate about whether EMT occurs in the adult organism has recently been revived (55, 56) . In addition to locally residing cells, myofibroblasts are generated from circulating progenitors, such as fibrocytes of hematopoietic origin and bone marrow-derived mesenchymal stem cells (38, (57) (58) (59) (60) (61) (62) (63) . However, differentiation of bone marrowderived cells into myofibroblasts was not confirmed by other studies (60, 64, 65) . Hence, to date it is still unclear which cell populations give rise to lung myofibroblasts and what their relative contributions to the development of lung fibrosis are. It is unlikely that this question can ever be answered in a definitive way. Conceivably, the type of injury, the local environment, and the progression of the disease will produce different myofibroblast populations.
MYOFIBROBLAST CONTRACTION LEADS TO TISSUE CONTRACTURE
A common feature of myofibroblasts arising from different conditions and precursors is the production of a collagen-rich ECM and its organization by applying high contractile forces (39) . Although myofibroblasts phenotypically resemble SMCs, the irreversible outcome of myofibroblast contraction suggests that it is somewhat differently regulated. We have recently published an extensive overview on this subject (66) and here provide a synopsis of this review. Development of contractile force in SMCs, myofibroblasts, and fibroblasts is regulated at the level of myosin light chain (MLC) phosphorylation. Phosphorylated MLC enables the myosin head to interact with actin filaments and to generate force. In SMCs, increased levels of cytosolic Ca 21 enhance the activity of the MLC kinase via the Ca 21 /calmodulin pathway (67, 68) . Force development is then terminated by MLC phosphatase activity. Conversely, in fibroblastic cells, the MLC phosphatase appears to be the key regulatory enzyme (69) . Fibroblast contraction is achieved by inactivation of the MLC phosphatase through the Rho-(associated) kinase (ROCK or ROK), a downstream target of the small GTPase RhoA (70) . Whereas changes in cytosolic Ca 21 regulate SMC contraction and RhoA tunes baseline force development (71, 72) , RhoA activity regulates fibroblast contraction and sufficiently high cytosolic Ca 21 levels ensure continued MLC activity (6) . Only a few studies have specifically addressed the regulation of myofibroblast contraction. Experiments with myofibroblastpopulated wound granulation tissue strips suggest RhoA as the chief regulator of myofibroblast contractile activity. Inhibition of MLC phosphatase using the phosphatase inhibitor calyculin was shown to be sufficient to induce strip contraction (73) , whereas increasing cytosolic Ca 21 by membrane depolarization and addition of Ca 21 ionophore had little effect on myofibroblast contraction of tissue strips and collagen gels (73) . This view of RhoA taking center stage was further supported by studies using three-dimensional myofibroblast-populated collagen gels (74) (75) (76) (77) . Using two-dimensional deformable culture substrates that allow visualization of cell contractile forces, inhibition of Rho was shown to block myofibroblast contraction, whereas stimulation with lysophosphatic acid, an upstream effector of Rho, enhanced force development (78, 79) . On the contrary, other studies claimed that the level of cytosolic Ca 21 is mainly regulating myofibroblast contraction. Application of calmodulin inhibitors to full-thickness rat skin wounds has been show to impair wound closure (80), a process that is driven by myofibroblast contraction (81, 82) . Stimulation with a variety of different agonists that all induce a Ca 21 response in SMCs induces contraction of myofibroblast-populated tissue strips (5, 73, (83) (84) (85) . In three-dimensional collagen gel cultures of rat ventricular and colon myofibroblasts, contraction was substantially regulated by the levels of cytosolic Ca 21 (86) (87) (88) , and interference with Ca 21 signaling had a more dramatic effect on collagen contraction by myofibroblastic hepatic stellate cells than modulation of RhoA-dependent processes (89) . Similar induction of myofibroblast contraction was obtained when treating twodimensional cell cultures with agonists that induce cytosolic Ca 21 transients (90, 91) . In addition to different experimental setups, the heterogeneous provenance of myofibroblasts is one possible reason for the apparent discrepancy concerning the importance of Ca 21 and RhoA for myofibroblast contraction. It is conceivable that different tissue and cell origins as well as the level of differentiation will have an impact on myofibroblast physiology.
In a recent cell culture study, we have tested the hypothesis that myofibroblasts use both contraction regulation mechanisms by simultaneously assessing local and global contraction events at the single-cell level in culture (78) . A key finding was that contractions of dorsal stress fibers engaged with ECM-coated microbeads were mediated by variations of cytosolic Ca 21 , whereas overall isometric cell tension was maintained through RhoA/ROCK-mediated contraction of ventral stress fibers engaged with an elastic rubber substrate ( Figure 3 ). Contractile events following periodic cytosolic Ca 21 increases (z1 contraction/100 s) were acting on a short range (z400 nm/ contraction) and comparably weak (z100 pN/contraction) as measured by atomic force microscopy (78) . This was in contrast to isometric contraction of the rubber substrate over hours with a force development of several micronewtons per cell (5, 78) or 5-10 nN/mm 2 per adhesion site (92) . It is tempting to speculate that the mechanical resistance (low for nonrestrained beads and high for rubber substrates) will determine what contraction mode is employed.
To date, it is unknown how myofibroblast contraction is regulated at the subcellular level in animal and human tissues. However, the in vitro findings have led to the development of an improved "lock-step" model of ECM remodeling (6). This model explains how global tissue remodeling can result from the contraction of single myofibroblasts and subsequent stabilization of tissues by secreted collagens and other ECM molecules (66, 78) . RhoA/ROCK signaling is responsible for promoting long-lasting and strong isometric cell contractions, which will generate slack in individual collagen fibrils. Such tension-released fibrils are then accessible to the weak and short-ranged microcontractions generated by periodic cytosolic Ca 21 transients. The gradually raising tension in locally pulled fibrils will increasingly counteract further local translocation. At this point, the new fibril configuration has to be stabilized, possibly by local collagen digestion, deposition of new collagen fibrils, and crosslinking with the existent ECM. Although the details of this putative remodeling step are not explored, it has been shown that collagen remodeling by matrix metalloproteinases can be regulated by mechanical tension (93, 94) . The stabilized ECM can then sustain tissue stress and myofibroblasts are able to respread. These processes would result in irreversible contractures characteristic for fibrosis rather than reversible contraction (6, 66, 78) .
THE STIFFNESS OF SCAR TISSUE: CAUSE AND CONSEQUENCE OF FIBROSIS
As discussed above, the most evident outcome of myofibroblast activity is tissue stiffening (95) . Myofibroblasts, in contrast to any of their precursors, produce excessive, poorly organized but dense collagen ECM. Scar tissue stiffness is expressed as Young's elastic modulus (in Pascals), which is defined as the force per unit area (stress) that is required to strain a material. High stress is needed to deform materials with high Young's modulus. The Young's modulus of normal lung tissue ranges between 1 and 5 kPa as measured by atomic force microscopy (96) .
Fibrotic tissue in the lung (96) (97) (98) (99) (100) and in other organs is up to 30 times stiffer (20-100 kPa) (95, (101) (102) (103) (104) (105) (106) . The fact that myofibroblast-generated fibrotic scars are stiffer than healthy parenchyma has important consequences for lung function. Stiff scar tissue impedes elastic expansion and contraction of the lung during breathing cycles. Accumulation of dense collagenous scar obstructs the regulation of airway diameter by airway SMCs and prevents efficient gas exchange (107) . Moreover, mechanical cues inherent to the stiff fibrotic ECM have a profound influence on myofibroblast differentiation and progression of fibrosis. Mechanical stress is one of the most potent factors controlling myofibroblast fate and development (95, 108) . In healing rat skin wounds, expression of a-SMA is accelerated by splinting the edges of full-thickness rat skin wounds with plastic frames, which increases tissue tension; the release of tension has the opposite effect (109) . A similar result is found after stretching human burn scar tissue in situ (28). Comparable controlled experiments with animal and human lung tissues have not yet been performed. Myofibroblasts express a-SMA when grown in attached (stressed) three-dimensional collagen gel culture but not in free-floating (relaxed) gels (110) . Application of mechanical force to ECM protein-coated magnetite beads that are attached to fibroblasts cultured on two-dimensional surfaces induces a-SMA expression (111) . Similarly, application of cyclic stretching forces stimulates EMT in cultured alveolar type II epithelial cells and induces lung fibrosis in an animal model of mechanical ventilation (112) .
The influence of substrate stiffness on the functional behavior of fibroblasts and myofibroblasts has been systematically studied using polymer culture substrates produced with stiffness within the elasticity range of normal and fibrotic tissue. Growing fibroblasts on pathologically stiff surfaces promotes myofibroblast activation, whereas exposure to healthy-soft substrates results in Figure 2 . Myofibroblast origins. The main myofibroblast progenitors after lung injury appear to be locally residing mesenchymal cells. In the liver, myofibroblasts are additionally recruited from activated hepatic stellate cells. In tumors and in fibrotic lung, liver, and kidney, differentiated myofibroblasts have been described to derive from epithelialand endothelial-to-mesenchymal transition (EMT), respectively. During atheromatous plaque formation, de-differentiating smooth muscle cells (i.e., that lose late smooth muscle cell markers) from the media are considered to be the major source of myofibroblastic cells. The relative contribution of bone marrow-derived circulating fibrocytes to the formation of differentiated myofibroblasts in different fibrotic lesions is unclear at present; it is conceivable that fibrocyte transdifferentiation also terminates at the protomyofibroblast stage. Finally, mesenchymal stem cells have been shown to acquire the differentiated myofibroblast phenotype in vitro and in vivo. TGF ¼ transforming growth factor. Modified and reprinted from Reference 39 by permission from the American Society for Investigative Pathology. acute loss of the myofibroblast phenotype (92, 96, 113) . Exposure of lung fibroblasts to pathological levels of ECM stiffness as seen during the end stages of fibrosis results in fibroproliferative behavior that is not unlike that seen in patients with idiopathic pulmonary fibrosis (96) . Such changes are usually observed after hours or 1 to 2 days following the change in mechanical culture conditions. In a recent study, however, we could demonstrate a long-ranged imprinting effect of substrate mechanics on the fibrotic cell character. Continued exposure to fibrosis-stiff culture surfaces primed lung fibroblasts towards the profibrotic myofibroblast phenotype, and the preservation of this stiffness-dependent fibrotic response was independent of a sustained stiffness stimulus (114) . Conversely, mechanically priming cells on healthy-soft culture substrates partly protected lung fibroblasts from myofibroblast activation by subsequent exposure to fibrosis-stiff substrates (Figure 4 ). By transplanting human lung fibroblasts from patients with lung fibrosis with different progression rates to humanized immunodeficient mouse, a recent study demonstrated that myofibroblasts can retain information to progress fibrosis (115) . It remains elusive how fibroblasts store mechanosensed information and whether such a proposed "mechanical memory" will actively promote or prevent disease progression in vivo. Tissue stiffness increases as a consequence of the ECM remodeling activities of fibroblasts and myofibroblasts (6, 110) . Hence, actively contracting cells generate the conditions that make them more contractile in a detrimental mechanical feed-forward loop. How is this cycle started immediately after an injury when contractile fibroblasts are absent? Data obtained from an animal model of liver fibrosis demonstrated that local tissue stiffening occurs during inflammation and precedes the activation of fibroblastic cells; it appears that such early mechanical changes would be sufficient to trigger the contracture cascade (116) . A number of mechanisms possibly account for early structural changes and tissue stiffening in these conditions. In the liver, collagen cross-linking by lysyl oxidases was implicated in initial tissue stiffening (116) . Moreover, fibrosis-specific and stable collagen cross-links are formed by the activities of LOXL2 (117) and specific lysyl hydroxylases (118) in different fibrotic conditions. It remains elusive whether inflammatory cells or activated epithelium (2, 119) in the injured lung can cause similar mechanical changes that will be sufficient to trigger the vicious cycle of myofibroblast activation and contraction.
MECHANICAL ACTIVATION OF TRANSFORMING GROWTH FACTOR-b1 PROVIDES A POSSIBLE CHECKPOINT IN FIBROSIS PROGRESSION
Myofibroblast mechanoregulation can occur at several levels. First, acute changes in the mechanical load determine the intracellular stress fiber localization of a-SMA (79, 92, 114) . Second, stress directly modulates a-SMA promoter activity and protein expression (111, 120) . Third, stress modulates the bioactivity of transforming growth factor (TGF)-b1, the major cytokine inducing myofibroblast differentiation. Different recent studies demonstrated force-dependent activation of latent TGF-b1 (79, (121) (122) (123) (124) (125) (126) . Together they support the concept that myofibroblasts can exert tensile forces on ECM-stored latent TGF-b1 via specific integrins and thereby activate this profibrotic cytokine.
TGF-b1 is the most potent profibrotic cytokine known (3, 127, 128) . Tissue expression levels of TGF-b1 are strongly elevated in different fibrotic lung diseases, including chronic airway remodeling in asthma (129) , chronic obstructive pulmonary disease (130, 131) , and interstitial pulmonary disease (132, 133) . Delivery of adenovirus producing active TGF-b1 to mouse lungs leads to accumulation of fibroblasts and collagen (134, 135) . Inhibition of TGF-b1 with function-blocking antibodies suppresses experimentally induced lung fibrosis (136) . One predominant detrimental role of TGF-b1 in causing lung fibrosis is the activation of myofibroblasts (4, 128) . Active TGF-b1 assembles a complex of TGF-b1-receptor type I and II in the cell membrane. The kinase activity of the complex phosphorylates SMAD 2/3, which translocates to the nucleus and activates transcription factors that regulate fibrogenic genes (137, 138) . TGF-b1 induces the expression of a-SMA and other components of the myofibroblast contractile cytoskeleton (139, 140) as well as collagen production (141) .
Despite the fact that TGF-b1 is an important therapeutic target to halt fibrosis, blocking the already active TGF-b1 in animal experiments and clinical tests had surprisingly little positive effect (142) . Moreover, TGF-b1 plays beneficial roles in controlling epithelial cell growth, inflammation, tissue homeostasis, and immune suppression in a variety of normal and pathologic adult tissues (138, (143) (144) (145) (146) (147) . This additional risk of side effects has stimulated the search for alternatives to specifically inhibit TGF-b1 profibrotic signaling. One possibility to achieve this aim is to interfere with the activation of latent TGF-b1 (148) (149) (150) (151) . TGF-b1 is synthesized as part of a pro-protein that is intracellularly cleaved to produce the small latent complex (SLC) ( Figure 5 ). Mature SLC consists of the TGF-b1 dimer, noncovalently linked to the dimeric latency-associated peptide (LAP) (152) . The majority of cell types secrete SLC together with latent TGF-b-binding protein-1 (LTBP-1) (152, 153) . LTBP-1 targets latent TGF-b1 as a large latent complex to the ECM by interacting with different proteins, including fibronectin and fibrillin (154) (155) (156) . These ECM deposits of latent TGF-b1 are accessible for cell-mediated activation (113, 157, 158) . Activation of latent TGF-b1 by its dissociation from LAP is promoted by various mechanisms, which differ according to cell type and physiological context (152, (158) (159) (160) . Transmembrane integrins have been shown to bind to and activate latent TGF-b1. Both LAP and LTBP-1 contain arginine-glycine-aspartic acid motifs for integrin docking (161) (162) (163) . Binding comprises all av integrins (avb1, avb3, avb5, avb6, and avb8) and integrins a5b1, a8b1, and aIIbb3 (164, 165) . Integrins avb5, avb6, avb8, and avb3 were shown to activate latent TGF-b1 using two different modes of action (113, 164) . The first depends on proteases that seem to be guided to the large latent complex by association mainly with integrin avb8 (150, 158, 166) .
The second integrin-mediated activation mechanism is independent of proteolysis and involves transmission of cell-derived forces to the large latent complex (113, 123, 126, 158, 164) . Integrin binding to LAP is essential for contraction-mediated TGF-b1 activation ( Figure 5 ) and inhibited by arginine-glycine-aspartic acid-and LAP-competitive peptides (79) . TGF-b1 activation efficiency increases with increasing ECM stiffness. Whereas compliant substrates appear to absorb the large deformations generated by myofibroblast contraction and thus protect the latent complex against conformational changes, the complex is stretchable on stiff substrates (79) . Hence, activation of TGF-b1 via integrin-mediated myofibroblast contraction represents a potential checkpoint in the progression of fibrosis. In other words, in the absence of exogenous active TGF-b1, autocrine generation of myofibroblasts only occurs after the ECM has been sufficiently pre-remodeled. Consistently, the ECM stiffness threshold for TGF-b1 activation by cultured myofibroblasts is lower (.5 kPa) (79) than for the induction and preservation of the myofibroblast phenotype (,16 kPa) (92) .
Currently available data supports the notion that myofibroblast traction on the large latent complex induces a conformational change in LAP that liberates active TGF-b1. We have recently measured the mechanical stress involved in TGF-b1 activation at the molecular level and demonstrated TGF-b1 release upon force transmission to LAP (122) . Our findings are consistent with previous studies suggesting that TGF-b1 activation involves conformational changes in the N-terminal portion of LAP, which confers latency by binding to TGF-b1 (167) (168) (169) (170) (171) . The recently published three-dimensional structure of the SLC (121) and force spectroscopy of SLC unfolding (122) revealed two structures that interact with TGF-b1 in this LAP region: the a1-helix and the latency lasso. Together, both domains form a "straitjacket" that traps TGF-b1 (121) ( Figure  5) . In contrast to the remaining LAP molecule, which is packed in a force-resistant structure, a1-helix and latency lasso are particularly susceptible to unfolding upon mechanical stretch due to their flexibility and their position opposite to the integrin binding site in the SLC (121) . Using the atomic force microscope to pull on SLC and the large latent complex led to three main discoveries: (1) Mechanical force applied to LAP can unfold the a1-helix and the latency lasso in the straitjacket.
(2) Simultaneous unfolding of both domains and full opening of the straitjacket is only possible when LAP is bound to LTBP-1.
(3) In the context of the large latent complex, fully unraveling the straitjacket requires lower forces (z40 pN) than unfolding of its individual stretches (z50 pN). Together these data favor an all-or-nothing mechanism of full TGF-b1 release by mechanical force ( Figure 5 ) and establish a direct link between the . Mechanical priming on fibrosis-stiff substrates results in persistent activation of lung myofibroblasts. Lung fibroblasts were explanted and subcultured for two passages on either 5-kPa healthy lung-soft or 100-kPa fibrotic lung-stiff collagen-coated silicone substrates. Cells were then transferred to soft or stiff surfaces and assessed after 12 hours and after 2 further passages (14 d) . Cells were immunostained for a-smooth muscle actin (a-SMA) (red) and nuclei (blue). Although stiff substrateprimed myofibroblasts demonstrated acute decrease of a-SMA stress fiber organization 12 hours after a shift to soft substrates, myofibroblast presence was reestablished and persisted even after 14 days of soft culture (114) . Scale bar ¼ 200 mm. mechanical and chemical factors regulating myofibroblast differentiation and ultimately causing fibrosis (113, 154, 155) . Inhibition of TGF-b1-activating integrins has promising therapeutic potential (172) . Knocking out integrin subunits that activate TGF-b1, including b6 (173), av (174), and b8 (175) , and mutation of the integrin-binding site in LAP (176) , recapitulates the TGF-b1 knockout mouse (177) . Knockout mice have defective vasculogenesis, are devoid of Langerhans cells, and spontaneously develop lung and skin inflammation. Importantly, the lungs of b6 integrin knockout mice are protected from bleomycin-induced fibrosis (178) . Controlled delivery of b6 integrin-blocking antibodies reduces lung fibrosis without negative side effects (179) . avb6 is the best studied integrin in the context of TGF-b1 activation and lung fibrosis, but only epithelial cells express this integrin (157, 176, 178, 180) . Epithelial cells are important in the onset of fibrosis in epithelialized tissues like the lung. Consequently, specific deletion of the TGF-b1 receptor RII in epithelial cells alone was sufficient to reduce bleomycin-induced experimental lung fibrosis (181) .
However, progression to end-stage pulmonary fibrosis depends on avb6 integrin-negative myofibroblasts (182, 183) .
The question remains which mesenchymal integrin is able to promote mechanical activation of latent TGF-b1. In lung myofibroblast cultures, contraction-mediated TGF-b1 activation is significantly reduced by inhibition of avb5 integrin (79, 123) . Integrin avb5 is up-regulated in culture lung myofibroblasts and strongly associates with fibrotic foci of diseased lung (184) . In airway SMCs, integrin avb5 is involved in TGF-b1 activation and chronic airway remodeling in animal models of asthma (185) . From these findings, one would expect that loss of avb5 integrin function protects from lung fibrosis similar to what has been shown for integrin avb6 (179) . Despite the fact that the phenotype of the avb5 knockout mouse is mild (186, 187) , these animals have yet to be challenged in fibrosis models in which TGF-b1 activation relies on myofibroblasts. Another possible candidate for TGF-b1 activation in the fibrotic lung is integrin a8b1, which is up-regulated in conjunction with myofibroblast differentiation in pulmonary, hepatic, and cardiac fibrosis (188, 189) . In cultured cardiac fibroblasts, a8b1 integrin is induced by TGF-b1 and up-regulated on myofibroblasts (189, 190) . However, the function of this integrin in lung fibroblasts is still unclear. When overexpressed in nonfibroblastic cells, a8b1 integrin strongly interacts with LAP but does not activate TGF-b1 (162) . Currently it is unknown whether this function is gained when expressed in highly contractile myofibroblasts.
CONCLUSIONS AND PERSPECTIVES
Myofibroblasts are attractive therapeutic targets to stop the progression of pulmonary fibrosis and to reduce the devastating structural changes in the lung architecture caused by this cell (191) . The fact that excessive contraction results in detrimental tissue contracture has nourished the idea to target contractile features of the myofibroblast. Specific inhibition of a-SMA with competitive peptides not only reduces myofibroblast contraction in culture and in rat wounds but decreases transcription of collagen type I (82) . Other strategies currently evaluate the potential of less specific drugs acting on cell contraction. The peptide hormone relaxin reduces the contractile activity of cultured lung fibroblast and bleomycin-induced accumulation of myofibroblasts and collagen in the lung (192) . Application of the ROCK-mediated contraction inhibitor Fasudil is effective in reducing myofibroblast-promoted experimental wound contraction (193) and development of kidney fibrosis (194) . Inhibition of thrombin similarly reduces lung myofibroblast contraction and leads to suppression of the fibrogenic phenotype (195) . Interference with force transmission to and mechanosensing from the ECM at sites of integrins provides alternative potentials to modulate myofibroblast action and differentiation. The most recent development in this area is to target specific integrins that myofibroblasts use to liberate active TGF-b1 by pulling on the large latent complex. Pharmacological interference with TGF-b1activating integrins could specifically counteract the harmful activity of active TGF-b1 but without inhibiting its beneficial effects on other cell types. Inhibition of specific integrins has already entered preclinical and clinical trials as therapy for other diseases, such as tumor treatment (196, 197) . Hence most of the antagonistic peptides and antibodies that have been developed for cancer therapies would be readily available for the treatment of lung fibrosis.
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